#USA #Atlanta #Clinical Trials #CAST Surgical #LevaLap

Celebrating Milestones in Surgical Innovation

Core Access Surgical Technologies, Inc. (CAST) has recently achieved a significant milestone in the field of minimally invasive surgery. The company's latest clinical trial manuscript has been accepted for publication by the Journal of the Society of Laparoscopic and Robotic Surgeons (JSLS), a leading platform dedicated to advancing surgical practices through peer-reviewed research.

Insights from the Study

The manuscript focuses on the LevaLap™ 1.0, a device that has begun making waves in operating rooms across the globe. This clinical study not only attests to its clinical effectiveness but also signifies its immense value for the new generation of surgeons, advanced practitioners, key opinion leaders, and robotic surgery specialists. Notably, the results will now be accessible on PubMed, expanding the reach of this vital information to the medical community.

According to the corresponding author, Dr. Ricardo Azziz, MD, MPH, the outcomes clear indicate that the LevaLap™ 1.0, even in the hands of experienced surgeons, provides substantial benefits by enhancing ease of use, control, speed, and safety for laparoscopic access to the abdomen with the Veress needle. He emphasized the growing necessity of this device as numerous practitioners around the world engage in such surgical operations, irrespective of their level of expertise.

Acknowledgements and Future Outlook

CAST extends its heartfelt gratitude to the JSLS for providing a respected platform that promotes the dissemination of its research. The JSLS plays an essential role in driving the evolution of minimally invasive surgery by facilitating the exchange of scientific knowledge and clinical innovations. CAST is honored to contribute to a global initiative aimed at improving surgical outcomes through rigorous research and collaboration.

Thomas A. Gordy, the CEO of CAST, expressed pride in this significant advancement, highlighting the global normalization of Veress needle access in laparoscopic surgery using the LevaLap™ 1.0 device. This multicenter, multinational study involved surgeons with diverse backgrounds and access techniques, which underscores the versatility and efficacy of the LevaLap device.

The Clinical Impact

The clinical impact of this accomplishment emphasizes the success of the LevaLap™ 1.0 access approach in enhancing surgical results and standardizing laparoscopic access. As further studies evolve, the expectation is that this device will continue to contribute positively to surgical methodologies and patient care.

At CAST, the mission is clear: to provide the medical community with superior and innovative solutions that deliver unique clinical and economic value. With ongoing advancements and improvements in surgical technology, CAST is committed to remaining at the forefront of healthcare innovation.

About CAST Surgical

Founded in the U.S., CAST specializes in designing, developing, manufacturing, and distributing minimally invasive access tools for laparoscopic surgery. Their focus on precision is integral to eliminating risks and normalizing efficient access. For more information about their products and innovations, visit www.castsurgical.com.

About JSLS

The Journal of the Society of Laparoscopic and Robotic Surgeons stands out as a premier peer-reviewed publication dedicated to minimally invasive surgery. It regularly ranks in the top 1% of more than 16,000 scientific journals on PubMed Central, indicating a high level of readership and engagement.

For investor inquiries, please reach out to Thomas A. Gordy at [email protected] or for media inquiries, contact CAST Surgical at +1-770-328-6642.